Continuous Glucose Monitoring

For noncritically ill hospitalized patients with diabetes, CGM is a reliable tool to improve glycemic control. However, more randomized studies are needed to assess these results in diverse populations.

Hybrid closed-loop insulin therapy adjusts insulin doses every 10 to 12 minutes by using a smartphone algorithm to communicate with continuous glucose monitoring devices and insulin pump systems.

A new study found that participants reported improved glycemic control and improved quality of life with smartwatch-integrated, do-it-yourself continuous glucose monitoring.

The 3 most common issues associated with higher satisfaction were “makes adjusting insulin easier,” “helps to keep low blood sugars from happening,” and “makes me feel safer knowing that I will be warned about low blood sugar before it happens.”

A 1-year observational follow-up of a 3-month randomized controlled trial provides insight into the benefits of advanced hybrid closed-loop system use in people with type 1 diabetes using multiple daily injections and self-monitoring of blood glucose.

Widespread use of continuous glucose monitoring was not found to attenuate the association between impaired awareness of hypoglycemia and diabetes-related distress.

Although investigators found a lack of strong evidence to support CGM programs in community pharmacy settings, studies in ambulatory care settings suggest that these programs are both feasible and beneficial.

Device adoption among minority patients with type 1 and type 2 diabetes remains low due to socioeconomic disparities.

Numerous tools, technology platforms, and interventions have been developed to help teens with the difficult emotional and physical weight of managing the disease.

Continuous glucose monitor and insulin pump use improved HbA1c.

When employed as a prescreening tool, care must be taken to avoid overdiagnosis of healthy individuals without diabetes.

When employed as a prescreening tool, care must be taken to avoid overdiagnosis of healthy individuals without diabetes.

The iLet Bionic Pancreas combines data from the Dexcom G6 CGM with different algorithms to deliver insulin throughout the day.

Doing small spurts of exercise throughout the day provide numerous benefits.

What can CGM's provide for individuals who don't have diabetes?

The MiniMed 780G has been available in Europe since 2020.

The drug is the first and only therapy to delay the onset of stage 3 type 1 diabetes.

Proposed legislation would cap the price of insulin at $35 for a 30-day supply.

Continuous glucose monitors are poised to change diabetes management for patients.

Pharmacists can provide support and guidance to patients during their month of fasting.